Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This study is a prospective Phase IV study to determine if the use of Everolimus results in
lower liver tumor recurrence and improved patient and graft survival after liver transplant
for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and
Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate
Mofetil/Azathioprine. Primary outcomes data is disease free survival (the time from
randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of
Hepatitis C, problems related to wound healing, hernia repair within the first 12 months,
hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant
diabetes, hypertension, and hyperlipidemia.